KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

Related Keywords

,Advanced Renal Cell Carcinoma ,Lenvatinib Plus Pembrolizumab ,Clear Cell ,Renal Cell Carcinoma ,Nrcc ,Advanced Rcc ,Non Clear Cell Rcc ,Non Clear Cell Renal Carcinoma ,Lenvatinib ,Pembrolizumab ,Keynote B61 ,